Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Methylprednisolone Addition in IVF Treatment of Infertile Couples

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2010 by Universitair Ziekenhuis Brussel.
Recruitment status was  Recruiting
Information provided by:
Universitair Ziekenhuis Brussel Identifier:
First received: August 27, 2010
Last updated: October 13, 2010
Last verified: October 2010

Hypothesis to be tested is whether follicular addition of Methylprednisolone can efficiently control late follicular progesterone rise during IVF treatment

Condition Intervention Phase
In Vitro Fertilization
Other: In vitro fertilization treatment for infertility
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Methylprednisolone vs. Placebo to Control Late Follicular Progesterone Elevation in GnRH-Antagonist IVF Cycles

Resource links provided by NLM:

Further study details as provided by Universitair Ziekenhuis Brussel:

Primary Outcome Measures:
  • Progesterone rise above on the day of HCG [ Time Frame: up to 14 days of follicular ovarian stimulation ] [ Designated as safety issue: No ]
    Incidence or high progesterone on the day of HCG triggering

Secondary Outcome Measures:
  • Clinical pregnancy rate [ Time Frame: Follow pregnancy until delivery ] [ Designated as safety issue: No ]
    Success rate in IVF cycles

Estimated Enrollment: 130
Study Start Date: January 2009
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Follicular Medrol
In an Antagonist protocol for IVF patients will also receive 4mg tabl. Methylprednisolone twice a day from the day 2 of ovarian stimulation and until the day of the pregnancy test on luteal day-14 post oocyte retrieval
Other: In vitro fertilization treatment for infertility
IVF treatment
Other Names:
  • pregnancy
  • progesterone
Placebo Comparator: No medrol group
Patients will receive only Antagonist protocol for IVF as usual
Other: In vitro fertilization treatment for infertility
IVF treatment
Other Names:
  • pregnancy
  • progesterone

Detailed Description:

The aim is to investigate any potential advantages of adding cortisone supplementation from the follicular phase onwards with regard to premature luteinization, oocyte quality, embryo quality and pregnancy outcome.


Ages Eligible for Study:   21 Years to 36 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • less than 36, more than 10 antral follicles, FSH<12

Exclusion Criteria:

  • endometriosis stage III&IV,
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01220791

Contact: Evangelos Papanikolaou, MD 0030 2310 424284

Biogenesis Recruiting
Thessaloniki, Pylaia, Greece, 55536
Contact: Evangelos Papanikolaou, MD,PhD    0030 2310 989160   
Sponsors and Collaborators
Universitair Ziekenhuis Brussel
Study Chair: Basil Tarlatzis, Professor BioGenesis
  More Information

Additional Information:
Responsible Party: Papanikolaou Evangelos, HRG Identifier: NCT01220791     History of Changes
Other Study ID Numbers: Medrol005
Study First Received: August 27, 2010
Last Updated: October 13, 2010
Health Authority: Greece: Ethics Committee

Keywords provided by Universitair Ziekenhuis Brussel:
late follicular phase
pregnancy rates

Additional relevant MeSH terms:
Methylprednisolone Hemisuccinate
Methylprednisolone acetate
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses processed this record on November 20, 2014